Does Rallies show 13F holders for DNA?

Yes. Rallies tracks hedge fund and 13F ownership data for DNA, including fund names, share counts, latest tracked quarter, and position changes when available.

Is DNA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for DNA. It does not provide personalized investment advice.

DNA (Ginkgo Bioworks Holdings, Inc.) Stock Analysis - Hedge Fund Holdings

Ginkgo Bioworks Holdings, Inc. (DNA) is a publicly traded Healthcare sector company. As of May 20, 2026, DNA trades at $7.65 with a market cap of $481.44M and a P/E ratio of -1.42. DNA moved +4.76% today. Year to date, DNA is -12.97%; over the trailing twelve months it is -3.38%. Its 52-week range spans $5.00 to $17.58. Analyst consensus is sell with an average price target of $8.50. Rallies surfaces DNA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns DNA stock?

Hedge funds tracked by Rallies that own DNA include Viking Global, Anchorage Capital, Glenview Capital, and Pinebridge Investments. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Ginkgo Bioworks Holdings, Inc..

DNA Key Metrics

Key financial metrics for DNA
Metric	Value
Price	$7.65
Market Cap	$481.44M
P/E Ratio	-1.42
EPS	$-5.36
Dividend Yield	0.00%
52-Week High	$17.58
52-Week Low	$5.00
Volume	617.81K
Avg Volume	0
Revenue (TTM)	$141.31M
Net Income	$-304.39M
Gross Margin	0.00%

Top Hedge Funds Holding DNA

Viking Global holds 3.58M shares of DNA, changed +0.00% as of Mar 31, 2026.
Anchorage Capital holds 1.75M shares of DNA, changed +0.00% as of Mar 31, 2026.
Glenview Capital holds 149.38K shares of DNA, changed +0.00% as of Dec 31, 2025.
Pinebridge Investments holds 140.94K shares of DNA, changed +358.21% as of Dec 31, 2023.

Latest DNA News

Ginkgo Bioworks Among Five in $58.76B Point-of-Care Diagnostics Market Growing 10% — May 12, 2026
Ginkgo Bioworks Q1 Revenue Plunges 49% to $19M, Plans to Double Nebula Lab — May 7, 2026
Ginkgo Bioworks Revives Extinct Plant Scents, Partners on Novel Perfumes — Mar 7, 2026
Ginkgo Bioworks Q4 Revenue Falls to $33M, Launches Cloud Lab and Sells Biosecurity — Mar 2, 2026
Ginkgo Bioworks Spins Off Biosecurity Unit, Doubles Autonomous Lab Racks to 100 — Feb 28, 2026

Recent DNA Insider Trades

Coen Steven P. sold 324 (~$2.58K) on Apr 17, 2026.
Coen Steven P. sold 33.17K (~$212.76K) on Apr 13, 2026.
Canton Barry sold 124.73K (~$802.49K) on Apr 10, 2026.

DNA Analyst Consensus

3 analysts cover DNA: 0 strong buy, 1 buy, 0 hold, 2 sell, 0 strong sell. Consensus rating is sell. Average price target: $8.50.

Common questions about DNA

Who owns DNA stock?: Hedge funds tracked by Rallies that own DNA include Viking Global, Anchorage Capital, Glenview Capital, and Pinebridge Investments. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Ginkgo Bioworks Holdings, Inc..
Does Rallies show 13F holders for DNA?: Yes. Rallies tracks hedge fund and 13F ownership data for DNA, including fund names, share counts, latest tracked quarter, and position changes when available.
Is DNA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for DNA. It does not provide personalized investment advice.